a combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid

JP2023550149A5Inactive Publication Date: 2024-11-29SANOFI SA(FR)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023530790
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-23
Filing Date
2021-11-23
Publication Date
2024-11-29
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Provided herein are combinations of abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions containing said combinations, and therapeutic uses thereof, particularly for the treatment of cancer, including breast cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The combination of abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, pharmaceutical compositions containing said combination, and the therapeutic use of said combination and pharmaceutical compositions, particularly for the treatment of cancer, are provided herein.

Background Art

[0002] Estrogen receptor α (ESR1) is expressed in the majority of breast tumors and enables them to respond to the mitogenic effects of estrogen.

[0003] 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, designated hereinbelow as "Compound (1)", is a selective estrogen receptor degrader (SERD), which has complete estrogen receptor antagonist properties and promotes proteasomal degradation of the estrogen receptor. This compound is disclosed in the patent application PCT / EP2017 / 053282 published as Patent Document 1:

Chemical Formula

[0004] Abemaciclib, also known as N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-amine, is a kinase inhibitor, and more particularly, an inhibitor of CDK4 and 6 (also referred to as a "CDK4 / 6" inhibitor). It has the following formula:

Chemical Formula

[0005] Abemaciclib is one of its trademark names, VERNEZIO (R) It will be marketed as a monotherapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression prior to chemotherapy in a metastatic state after endocrine therapy. It will also be marketed in combination with the endocrine therapy fulvestrant for the treatment of women with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression after endocrine therapy. [Prior art documents] [Patent Documents]

[0006] [Patent Document 1] WO 2017 / 140669 [Overview of the Initiative] [Problems that the invention aims to solve]

[0007] There is always a need to discover new antitumor treatments. Now, in this specification, it is shown that the combination of compound (1) with abemaciclib is well-acceptable and, compared to each active ingredient alone, exhibits a synergistic effect, demonstrating significant antitumor efficacy and inducing tumor quiescence. [Means for solving the problem]

[0008] A combination comprising compound (1) and abemaciclib is provided herein.

[0009] In the combinations provided herein, compound (1) may exist not only in the form of a zwitterionic ion (i.e., an overall neutral molecule having an acidic group and a basic group), but also in the form of an addition salt with an acid or a base. Such addition salts may be used in the above combinations. Accordingly, combinations comprising compound (1), or a pharmaceutically acceptable salt thereof, with abemaciclib are provided herein.

[0010] In one embodiment, a combination of compound (1), or a pharmaceutically acceptable salt thereof, with abemaciclib exhibits a therapeutic synergistic effect. The combination exhibits a therapeutic synergistic effect if its therapeutic effect is superior to the cumulative effect of each active agent of the combination alone.

[0011] In another embodiment, compound (1), or a pharmaceutically acceptable salt thereof, and abemaciclib are administered orally.

[0012] Combinations of compound (1), or a pharmaceutically acceptable salt thereof, with abemaciclib for use as a pharmaceutical agent are also provided herein.

[0013] Pharmaceutical compositions comprising compound (1), or a pharmaceutically acceptable salt thereof, and abemaciclib, in addition to at least one pharmaceutically acceptable excipient, are also provided herein.

[0014] The excipients are selected from common excipients known to those skilled in the art. More specifically, the excipients are selected from those useful for oral administration in any form (liquid solutions, dispersions or suspensions, tablets, capsules or similar).

[0015] In another embodiment, compound (1), or a pharmaceutically acceptable salt thereof, and abemaciclib can be administered simultaneously, separately, or at intervals (sequential administration). Thus, the combinations and pharmaceutical compositions provided herein are not limited to those obtained by physical combination of the components in a single unit dosage, but also enable separate administrations that may be simultaneous or sequential (also referred to as "spaced" or "extended") over a period of time.

[0016] i) a first pharmaceutical composition comprising compound (1), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient; (ii) a second pharmaceutical composition comprising abemaciclib and at least one pharmaceutically acceptable excipient; A pharmaceutical kit comprising the above is also provided herein, where the first pharmaceutical composition and the second pharmaceutical composition are in separate compartments and are intended to be administered independently, and each administration can be simultaneous with or spaced (sequential) relative to the other.

[0017] In the above combinations, pharmaceutical compositions and pharmaceutical kits, compound (1) or a pharmaceutically acceptable salt thereof and abemaciclib are advantageously present in effective dosages adapted in consideration of the pathological conditions and states of the patients to be treated in whom the combination, pharmaceutical composition or pharmaceutical kit is administered. In particular, for abemaciclib, the recommended starting dose for adult patients is 200 mg twice daily for monotherapy, taken orally with or without food, and 150 mg twice daily as combination therapy with fulvestrant.

[0018] The above pharmaceutical compositions and kits for use in the treatment of cancer, further comprising a combination of compound (1), or a pharmaceutically acceptable salt thereof, and abemaciclib, are also provided herein.

[0019] Compound (1) or a pharmaceutically acceptable salt thereof for use in the treatment of cancer by co-administration with abemaciclib is also provided herein.

[0020] Abemaciclib for use in the treatment of cancer by co-administration with compound (1) or a pharmaceutically acceptable salt thereof is also provided herein.

[0021] Co-administration is herein understood as the administration of the active ingredients, for each of the active ingredients, separately, simultaneously or spaced (sequentially) to a patient who requires it.

Mode for Carrying Out the Invention

[0022] In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and abemaciclib are administered in a therapeutically effective amount. "Therapeutically effective amount" means an amount of an active ingredient or combination of active ingredients that is sufficient to affect the treatment of such a disease when administered to a patient for treating the disease. The "therapeutically effective amount" varies depending on the disease and its severity, as well as the age, weight, etc. of the mammal to be treated (e.g., a human patient).

[0023] In some embodiments, compound (1) or a pharmaceutically acceptable salt thereof and abemaciclib are administered in an amount that exhibits therapeutic synergism.

[0024] In another embodiment, the cancer is a hormone-dependent cancer.

[0025] In another embodiment, the cancer is an estrogen receptor-dependent cancer, and particularly the cancer is an estrogen receptor α-dependent cancer.

[0026] In another embodiment, the cancer is resistant to anti-hormone treatment.

[0027] In another embodiment, the cancer is a cancer that has a wild-type estrogen receptor.

[0028] In another embodiment, the cancer is a cancer having deregulated function of the estrogen receptor, which is associated with at least one epigenetic alteration and genetic alteration of the estrogen receptor, such as mutation, amplification, or splice variant.

[0029] In another embodiment, the cancer is a cancer having a mutated estrogen receptor.

[0030] In another embodiment, the cancer is estrogen-sensitive cancer.

[0031] In another embodiment, the cancer is breast cancer, more specifically estrogen receptor-positive breast cancer (more specifically, ERα-positive breast cancer), or its metastases, such as brain metastases.

[0032] Also provided herein is a method for treating the conditions described above, in particular breast cancer, comprising administering a therapeutically effective amount of compound (1), or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of abemaciclib to a patient in need thereof.

[0033] Methods for treating the conditions described above, particularly breast cancer, are also provided herein, which include administering the above-mentioned pharmaceutical composition or pharmaceutical kit to a patient in need thereof.

[0034] Methods for treating the conditions described above, particularly breast cancer, including administering the above combinations to patients in need, are also provided herein.

[0035] A method for treating the conditions described above, particularly breast cancer, is also provided herein, comprising co-administering compound (1) or a pharmaceutically acceptable salt thereof and abemaciclib to a patient in need thereof. In the above method, compound (1) or a pharmaceutically acceptable salt thereof is administered simultaneously with abemaciclib or at a time interval.

[0036] Also provided herein is a method for treating the conditions described above, particularly breast cancer, comprising co-administering abemaciclib and compound (1) or a pharmaceutically acceptable salt thereof to a patient in need thereof. In the above method, abemaciclib is administered simultaneously with or at a time interval from compound (1) or a pharmaceutically acceptable salt thereof.

[0037] A method for treating cancer is also provided herein, comprising administering a therapeutically effective amount of the compound 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidine-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]anulene-2-carboxylic acid, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of abemaciclib to a patient in need.

[0038] A method for treating cancer is also provided herein, comprising administering an effective dose of abemaciclib to a patient receiving treatment with the compound 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidine-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]anulen-2-carboxylic acid or a pharmaceutically acceptable salt thereof.

[0039] A method for treating cancer is also provided herein, comprising administering a therapeutically effective dose of abemaciclib to a patient who has been stabilized with the compound 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidine-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]anulen-2-carboxylic acid or a pharmaceutically acceptable salt thereof.

[0040] A method for treating cancer is also provided herein, comprising administering a therapeutically effective dose of abemaciclib to a patient in need thereof, wherein the patient is also being treated with the compound 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidine-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]anulen-2-carboxylic acid, or a pharmaceutically acceptable salt thereof.

[0041] In one embodiment of the above method, the patient is a human patient.

[0042] Compound (1), or a pharmaceutically acceptable salt thereof, and combinations with abemaciclib are also provided herein for the manufacture of agents useful in treating the conditions described above, particularly breast cancer.

[0043] The use of compound (1), or a pharmaceutically acceptable salt thereof, in the manufacture of a drug useful for treating the conditions described above, particularly breast cancer, when administered concurrently with abemaciclib, is also provided herein.

[0044] The use of abemaciclib in the manufacture of agents useful for treating the above-mentioned conditions, particularly breast cancer, by co-administration with compound (1) or a pharmaceutically acceptable salt thereof, is also provided herein.

[0045] - Packaging materials; - The combination, pharmaceutical composition, or pharmaceutical kit defined above; and - A label or accompanying document included in the packaging material indicating that the combination, pharmaceutical composition, or pharmaceutical kit is administered to a patient for the treatment of cancer. Products, packages, or dosage units including the above are also provided herein. [Examples]

[0046] The following examples illustrate the pharmacological results obtained in mice using compound (1), abemaciclib, and combinations thereof on xenografts of breast cancer cell lines.

[0047] Evaluation of the efficacy of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidine-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]anulen-2-carboxylic acid combined with abemaciclib against subcutaneous mammary cancer cell line xenografts in female nude mice. In this study, the antitumor efficacy of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidine-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]anulen-2-carboxylic acid ("Compound (1)") combined with abemaciclib was investigated after 22 days of subcutaneous treatment with MCF7-Y537S human breast cancer cell line xenografts in female nude mice.

[0048] The treated groups included those receiving compound (1) alone at 20 mg / kg, abemaciclib alone at 70 mg / kg, and those receiving compound (1) and abemaciclib in combination with the same dose and administration regimen.

[0049] For 22 days, compound (1) was administered orally twice daily (BID), and abemaciclib was administered orally once daily (QD). Antitumor efficacy was evaluated by tumor volume measurement.

[0050] 1: Experimental Procedure 1-1: Animals, cell lines, compounds Female BALB / c nude mice were obtained from Shanghai Sino-British SIPPR / BK Laboratory Animal Co., LTD (Shanghai, CHINA). The animals were acclimatized for at least 4 days prior to trial registration. The mice were 6–8 weeks old and weighed between 18 and 24 grams at the start of treatment. These animals were housed under conditions outlined in the guidelines approved by the Institutional Animal Care and Use Committee (IACUC) at WuXi AppTec, in accordance with the guidelines of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC).

[0051] Parental MCF7 cells were transferred to the American Type Culture Collection (ATCC). (R) HTB-22 TMThe MCF7-Y537S (ESR1) cell line was obtained from the Sanofi Biology Discovery Group. The Y537S mutation was introduced into the ESR1 construct (GenBank NM_000125.3) by site-directed mutagenesis (Toy W. et al., Cancer Discovery, 2017, 7, 277-287). The construct was transfected into MCF7 cells selected for their proliferation in the absence of estradiol. MCF-Y537S is an ESR1 mutation that confers estrogen-dependent activity to ERα (estrogen receptor alpha) and contributes to endocrine resistance diseases (Robinson DR et al., Nat Genet., 2013, 45 (12), 1446-1451). Cells were grown in Eagle's Minimal Essential Medium (EMEM) supplemented with 10% fetal bovine serum (FBS) and human insulin at 5% CO2 and 37°C. The cells were harvested in 0.25% trypsin-EDTA, washed with phosphate-buffered saline (PBS), and resuspended in PBS containing 75% Matrigel. (20 × 10⁴ cells per mouse) 6 The cells were subcutaneously (SC) transplanted into the right flank of female nude mice.

[0052] If an MCF7-Y537S tumor was established, the tumor was set aside as a tumor stock for fragment transplantation. The tumor was continuously grown subcutaneously by fragment tissue transplantation. The fragment tumor tissue was subcutaneously transplanted into the right flank of female nude mice. 28 mice were assigned to this experiment.

[0053] Abemaciclib (manufacturer: Sanofi; lot number: VAC.DLE20.006.1) was compounded into 40% SBE-β-CD in HCl 0.1N pH 3.0. Compound (1) was prepared in 5% Solutol HS15 (purchased from Sigma) at pH 3.0.

[0054] Dosage volume of compound (1) and abemaciclib for oral administration: 10 ml / kg via oral enteral nutrition.

[0055] Dosage: Compound (1) 20 mg / kg and abemaciclib 70 mg / kg in the above volume.

[0056] 1-2: Test design, evaluation items Animals necessary for the experiment (with some extras added) were pooled, and MCF7-Y537S tumor fragment tissue was transplanted. On day 0 (20 days after transplantation), mice were pooled and randomly assigned to treatment and control groups (7 mice per group), with a median tumor volume of 173 mm² for each group. 3 The treatment with compound (1) and abemaciclib was initiated on day 0. For 22 days, compound (1) was administered at 20 mg / kg BID (8-hour intervals), and abemaciclib was administered at 70 mg / kg QD. Animal body weight was assessed daily.

[0057] The dosage was expressed in mg / kg and based on the daily body weight of each animal. Animals treated with a vehicle were used as controls. Mice were examined daily and adverse clinical reactions were recorded. Individual mice were weighed daily until the end of the experiment. Mice were euthanized if pathological conditions or weight loss of ≥20% were observed. Tumors were measured twice a week with a caliper until final sacrifice. Tumor size was approximately 2000 mm. 3 If the condition of the animal reached a certain level, or if there was a problem (40% of the tumor area was ulcerated), the animal was euthanized and the date of death was recorded. The solid tumor volume was estimated from two-dimensional tumor measurements and calculated according to the following equation:

number

[0058] Toxicity assessment items: If weight loss or animal death could not be considered drug-related under specific circumstances, a drug dose that resulted in a 15% weight loss over three consecutive days, a 20% weight loss in one day, or 10% or more drug-related death in an individual mouse was considered an excessive toxic dose. Examples include animal handling problems such as misgavage during enteral feeding, tumor model-related problems such as tumor-induced cachexia resulting in weight loss that may be observed in control or vehicle-treated groups, and excessive tumor ulceration. Mice with drug-unrelated death or significant weight loss were not considered toxic and were excluded from statistical analysis. Animal body weight included tumor weight.

[0059] Effectiveness evaluation items: The primary efficacy endpoint includes tumor volume change from baseline, summarized by the ratio of median tumor volume changes from baseline between the treatment group and the control group (ΔT / ΔC). Tumor volume change for each animal was calculated daily for both the treatment (T) and control (C) groups by subtracting the tumor volume on the day of the first treatment (stage diagnosis day) from the tumor volume on a specific observation day. The median ΔT was calculated for the treatment group, and the median ΔC was calculated for the control group. The ratio ΔT / ΔC was calculated, and then the percentage:

number

[0060] A ΔT / ΔC ≤ 40% is considered therapeutically active, ΔT / ΔC = 0% is considered tumor quiescence, and ΔT / ΔC < 0% is considered tumor regression (highly active). A ΔT / ΔC > 40% is considered therapeutically inactive.

[0061] The tumor regression percentage is defined as the percentage reduction in tumor volume in the treatment group on a given observation day, compared to its volume at the start of the study. For each animal and at a given time point (t), the regression percentage was calculated using the following formula:

number

[0062] Next, the median regression percentage for a given group on a given day was calculated by taking the median of the individual regression percentages calculated for each animal in that group. Unless the median regression percentage does not represent the activity of the group, the day of calculation is determined by the day on which ΔT / ΔC was calculated. In this case, the day is determined by the first day on which the median regression percentage is maximum.

[0063] 1-3: statistical analysis A two-way Anova analysis using treatment and day (repetition) factors was performed for tumor volume change from baseline. Subsequently, a contrast analysis with Bonferroni-Helm correction for multiplicity was performed to compare all treatment groups with the control group, and the combinations were compared to each individual drug at the dose included in the combination for each day from 0 to 22.

[0064] In the diagram, the median and median absolute deviation (MAD) for each group are shown for each measurement day.

[0065] In the table, the median and normalized MAD (nMAD = 1.4826 * MAD) for each group are reported for each measurement day.

[0066] The change in tumor volume from baseline was calculated for each animal and each day by subtracting the tumor volume on the day of the first treatment (day 0) from the tumor volume on a specific observation day.

[0067] All statistical analyses were performed using SAS version 9.2 software. A probability of less than 5% (p<0.05) was considered statistically significant.

[0068] 2: result The combination of compound (1) 20 mg / kg BID and abemaciclib 70 mg / kg QD over 22 days, as well as the combination of compound (1) and abemaciclib in these doses and dosing regimens, was well tolerable, and no significant weight loss was observed in this study.

[0069] Compound (1) at a dose of 20 mg / kg BID for 22 days did not have a statistically significant antitumor effect against tumor growth, with a ΔT / ΔC value of 47% (p=0.9411) on day 22. Abemaciclib at a dose of 70 mg / kg QD for 22 days induced a statistically significant antitumor effect, with a ΔT / ΔC value of 19% (p=0.0002) on day 22. When compound (1) was combined with abemaciclib at 70 mg / kg and compound (1) at 20 mg / kg using the same dosing regimen as BID for compound (1) and QD for abemaciclib, this combination treatment showed a statistically significant antitumor efficacy (tumor quiescence), with a ΔT / ΔC value of -4% (p<0.0001) on day 22. Statistical analysis showed that the combination effect was significantly different (p<0.0001) when compared to compound (1) alone or abemaciclib alone on day 22.

[0070] Detailed results are shown in Tables 1-3 and Figures 1 and 2 below. [Brief explanation of the drawing]

[0071] [Figure 1] Figure 1: Antitumor activity of compound (1) in combination with abemaciclib against subcutaneous human breast cancer cell line MCF7-Y537S xenografts in nude mice: evolution of tumor volume. The curves represent the median + or -MAD (median absolute deviation) for each group at each day. [Figure 2] Figure 2: Antitumor activity of compound (1) in combination with abemaciclib against subcutaneous human breast cancer cell line MCF7-Y537S xenografts in nude mice: change in tumor volume from baseline at day 22. The dots represent the change in individual tumor volume from baseline at day 22, and the bar represents the median.

[0072] From this experiment, we concluded that compound (1), administered at 20 mg / kg twice daily in combination with the CDK4 / 6 inhibitor abemaciclib at 70 mg / kg once daily, induced significantly superior antitumor efficacy compared to the single agent alone in a xenograft model of the MCF7-Y537S human breast cancer cell line in nude mice, and also induced inhibition of tumor growth and tumor quiescence.

[0073] [Table 1]

[0074] [Table 2]

[0075] [Table 3]

Claims

1. A combination comprising 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharma- ceutically acceptable salt thereof, and abemaciclib.

2. The combination according to claim 1, which exhibits therapeutic synergy.

3. 3. A combination according to claim 1 or 2 for use in the treatment of cancer.

4. The combination for use according to claim 3, wherein the cancer is breast cancer.

5. The combination according to any one of claims 1 to 4, wherein 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharma- ceutically acceptable salt thereof, and abemaciclib are administered simultaneously or at a certain interval.

6. A pharmaceutical composition comprising 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharma- ceutically acceptable salt thereof, abemaciclib, and at least one pharma- ceutically acceptable excipient.

7. 7. The pharmaceutical composition of claim 6 for use in the treatment of cancer.

8. The pharmaceutical composition for use according to claim 7, wherein the cancer is breast cancer.

9. The compound 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharma- ceutically acceptable salt thereof, for use in the treatment of cancer by co-administration with abemaciclib.

10. 9. The compound for use in the treatment of cancer according to claim 8, administered separately from abemaciclib, simultaneously with abemaciclib, or spaced apart from abemaciclib.

11. 1. Abemaciclib for use in the treatment of cancer by co-administration with the compound 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharma- ceutically acceptable salt thereof.

12. 12. Abemaciclib for use in the treatment of cancer according to claim 11, administered separately, simultaneously or at a time with the compound 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharma- ceutically acceptable salt thereof.

13. (i) a first pharmaceutical composition comprising 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid, or a pharma- ceutically acceptable salt thereof, and at least one pharma- ceutically acceptable excipient; (ii) a second pharmaceutical composition comprising abemaciclib and at least one pharma- ceutically acceptable excipient; A pharmaceutical kit comprising: The above pharmaceutical kit, wherein the first pharmaceutical composition and the second pharmaceutical composition are in separate compartments and are intended to be administered independently, the administration of each being simultaneous or spaced in time with respect to the other.